OptMed Obtains $6,009,950 New Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    420 Lexington Ave. New York, NY 10017
  • Company Description
    Our lead biosurgical product in development—
    Devakor, a topical skin adhesive—is a replacement for surgical sutures. OptMed’s therapeutics in development are based on proprietary new indications for a widely used drug to provide targeted relaxation of smooth muscle in the lower urinary tract. Local delivery of this drug provides a highly differentiated approach to treating a range of genitourinary disorders.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor

Trending on Xconomy